Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexane- carbonyl)-D-phenylalanine (A-4166)

Takao Ikenoue, Megumi Akiyoshi, Shoji Fujitani, Kyoko Okazaki, Nobuo Kondo, Toshio Maki

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

1 (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166), a novel oral hypoglycaemic agent is a non-sulphonylurea insulin secretagogue. 2 We investigated the insulin-releasing action and hypoglycaemic effect of A-4166 compared to sulphonylureas in vitro and in vivo. 3 A-4166 stimulated insulin secretion from rat freshly isolated pancreatic islets at concentrations from 3 x 10-6 M to 3 x 10-4 M in the presence of 2.8 mM glucose. There was no obvious difference in glucose dependency between the insulinotropic effect of A-4166 and that of glibenclamide, and no additive or synergistic effect was observed between these two drugs. 4 A-4166 displaced [3H]-glibenclamide bound to intact HIT-T15 cells in a concentration-dependent manner. The K(i) value was 4.34 ± 0.04 x 10-7 M, and the displacement potency of A-4166 was between that of glibenclamide and tolbutamide, being similar to that of gliclazide. 5 In fasted beagle dogs, A-4166 showed a dose-dependent hypoglycaemic effect after oral administration over the range 1 to 10 mg kg-1. The hypoglycaemic action of A-4166 showed an earlier onset and a shorter duration than that of sulphonylureas. 6 Simultaneous measurement of plasma insulin levels revealed that the hypoglycaemic effect of A-4166 was caused by a rapid-onset and brief burst of insulin secretion. 7 The pharmacokinetic profile of A-4166 was consistent with the changes of the blood glucose and plasma insulin levels. 8 Although the in vitro insulin-releasing effect of A-4166 was similar to that of sulphonylureas, its hypoglycaemic effect was more rapid and shorter-lasting, associated with rapid absorption and clearance. Thus, A-4166 may be useful in suppressing postprandial hyperglycaemia in patients with non-insulin-dependent diabetes mellitus.

Original languageEnglish
Pages (from-to)137-145
Number of pages9
JournalBritish Journal of Pharmacology
Volume120
Issue number1
DOIs
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

nateglinide
Phenylalanine
Hypoglycemic Agents
Insulin
Glyburide
isopropylcyclohexane
Gliclazide
Glucose
Tolbutamide

Keywords

  • A-4166
  • Insulin secretion
  • Islets of langerhans
  • Sulphonylurea

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexane- carbonyl)-D-phenylalanine (A-4166). / Ikenoue, Takao; Akiyoshi, Megumi; Fujitani, Shoji; Okazaki, Kyoko; Kondo, Nobuo; Maki, Toshio.

In: British Journal of Pharmacology, Vol. 120, No. 1, 1997, p. 137-145.

Research output: Contribution to journalArticle

Ikenoue, Takao ; Akiyoshi, Megumi ; Fujitani, Shoji ; Okazaki, Kyoko ; Kondo, Nobuo ; Maki, Toshio. / Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexane- carbonyl)-D-phenylalanine (A-4166). In: British Journal of Pharmacology. 1997 ; Vol. 120, No. 1. pp. 137-145.
@article{65004842c0bc42f1a11cda97dc573963,
title = "Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexane- carbonyl)-D-phenylalanine (A-4166)",
abstract = "1 (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166), a novel oral hypoglycaemic agent is a non-sulphonylurea insulin secretagogue. 2 We investigated the insulin-releasing action and hypoglycaemic effect of A-4166 compared to sulphonylureas in vitro and in vivo. 3 A-4166 stimulated insulin secretion from rat freshly isolated pancreatic islets at concentrations from 3 x 10-6 M to 3 x 10-4 M in the presence of 2.8 mM glucose. There was no obvious difference in glucose dependency between the insulinotropic effect of A-4166 and that of glibenclamide, and no additive or synergistic effect was observed between these two drugs. 4 A-4166 displaced [3H]-glibenclamide bound to intact HIT-T15 cells in a concentration-dependent manner. The K(i) value was 4.34 ± 0.04 x 10-7 M, and the displacement potency of A-4166 was between that of glibenclamide and tolbutamide, being similar to that of gliclazide. 5 In fasted beagle dogs, A-4166 showed a dose-dependent hypoglycaemic effect after oral administration over the range 1 to 10 mg kg-1. The hypoglycaemic action of A-4166 showed an earlier onset and a shorter duration than that of sulphonylureas. 6 Simultaneous measurement of plasma insulin levels revealed that the hypoglycaemic effect of A-4166 was caused by a rapid-onset and brief burst of insulin secretion. 7 The pharmacokinetic profile of A-4166 was consistent with the changes of the blood glucose and plasma insulin levels. 8 Although the in vitro insulin-releasing effect of A-4166 was similar to that of sulphonylureas, its hypoglycaemic effect was more rapid and shorter-lasting, associated with rapid absorption and clearance. Thus, A-4166 may be useful in suppressing postprandial hyperglycaemia in patients with non-insulin-dependent diabetes mellitus.",
keywords = "A-4166, Insulin secretion, Islets of langerhans, Sulphonylurea",
author = "Takao Ikenoue and Megumi Akiyoshi and Shoji Fujitani and Kyoko Okazaki and Nobuo Kondo and Toshio Maki",
year = "1997",
doi = "10.1038/sj.bjp.0700875",
language = "English",
volume = "120",
pages = "137--145",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexane- carbonyl)-D-phenylalanine (A-4166)

AU - Ikenoue, Takao

AU - Akiyoshi, Megumi

AU - Fujitani, Shoji

AU - Okazaki, Kyoko

AU - Kondo, Nobuo

AU - Maki, Toshio

PY - 1997

Y1 - 1997

N2 - 1 (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166), a novel oral hypoglycaemic agent is a non-sulphonylurea insulin secretagogue. 2 We investigated the insulin-releasing action and hypoglycaemic effect of A-4166 compared to sulphonylureas in vitro and in vivo. 3 A-4166 stimulated insulin secretion from rat freshly isolated pancreatic islets at concentrations from 3 x 10-6 M to 3 x 10-4 M in the presence of 2.8 mM glucose. There was no obvious difference in glucose dependency between the insulinotropic effect of A-4166 and that of glibenclamide, and no additive or synergistic effect was observed between these two drugs. 4 A-4166 displaced [3H]-glibenclamide bound to intact HIT-T15 cells in a concentration-dependent manner. The K(i) value was 4.34 ± 0.04 x 10-7 M, and the displacement potency of A-4166 was between that of glibenclamide and tolbutamide, being similar to that of gliclazide. 5 In fasted beagle dogs, A-4166 showed a dose-dependent hypoglycaemic effect after oral administration over the range 1 to 10 mg kg-1. The hypoglycaemic action of A-4166 showed an earlier onset and a shorter duration than that of sulphonylureas. 6 Simultaneous measurement of plasma insulin levels revealed that the hypoglycaemic effect of A-4166 was caused by a rapid-onset and brief burst of insulin secretion. 7 The pharmacokinetic profile of A-4166 was consistent with the changes of the blood glucose and plasma insulin levels. 8 Although the in vitro insulin-releasing effect of A-4166 was similar to that of sulphonylureas, its hypoglycaemic effect was more rapid and shorter-lasting, associated with rapid absorption and clearance. Thus, A-4166 may be useful in suppressing postprandial hyperglycaemia in patients with non-insulin-dependent diabetes mellitus.

AB - 1 (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166), a novel oral hypoglycaemic agent is a non-sulphonylurea insulin secretagogue. 2 We investigated the insulin-releasing action and hypoglycaemic effect of A-4166 compared to sulphonylureas in vitro and in vivo. 3 A-4166 stimulated insulin secretion from rat freshly isolated pancreatic islets at concentrations from 3 x 10-6 M to 3 x 10-4 M in the presence of 2.8 mM glucose. There was no obvious difference in glucose dependency between the insulinotropic effect of A-4166 and that of glibenclamide, and no additive or synergistic effect was observed between these two drugs. 4 A-4166 displaced [3H]-glibenclamide bound to intact HIT-T15 cells in a concentration-dependent manner. The K(i) value was 4.34 ± 0.04 x 10-7 M, and the displacement potency of A-4166 was between that of glibenclamide and tolbutamide, being similar to that of gliclazide. 5 In fasted beagle dogs, A-4166 showed a dose-dependent hypoglycaemic effect after oral administration over the range 1 to 10 mg kg-1. The hypoglycaemic action of A-4166 showed an earlier onset and a shorter duration than that of sulphonylureas. 6 Simultaneous measurement of plasma insulin levels revealed that the hypoglycaemic effect of A-4166 was caused by a rapid-onset and brief burst of insulin secretion. 7 The pharmacokinetic profile of A-4166 was consistent with the changes of the blood glucose and plasma insulin levels. 8 Although the in vitro insulin-releasing effect of A-4166 was similar to that of sulphonylureas, its hypoglycaemic effect was more rapid and shorter-lasting, associated with rapid absorption and clearance. Thus, A-4166 may be useful in suppressing postprandial hyperglycaemia in patients with non-insulin-dependent diabetes mellitus.

KW - A-4166

KW - Insulin secretion

KW - Islets of langerhans

KW - Sulphonylurea

UR - http://www.scopus.com/inward/record.url?scp=0031038234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031038234&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0700875

DO - 10.1038/sj.bjp.0700875

M3 - Article

VL - 120

SP - 137

EP - 145

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -